Entera Bio FY2023 net loss narrows to $8.9M; cash runway into Q2 2025; five oral peptide programs on track

Entera Bio Ltd.

Net loss for FY2023 was $8.9M ($0.31/share), down from $13.1M ($0.45/share) in FY2022.
Cash and cash equivalents $11.0M as of Dec 31, 2023; sufficient to fund operations through Q2 2025.
R&D expenses decreased to $4.5M from $5.8M; G&A decreased to $4.4M from $7.3M due to cost cuts.
Key 2024 milestones: Phase 1 PK data for EB612 (H1), pre-IND PK for GLP-2 (H1) and OXM (mid-2024), SABRE update.
Advancing five oral peptide programs: EB613 (osteoporosis), EB612 (hypoparathyroidism), GLP-2, OXM, stress fractures.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Entera Bio Ltd. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 8 , 2024, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-24-000879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.